valu usd unless otherwis note
increas pt potenti ultomiri switch
pipelin break rang bind
view see expand pipelin larg unappreci
amidst continu percept revenu stream larg
concentr overhang potenti existenti gener
competit risk follow day includ sever
late-stag clinic develop program valuat
detail rational see downsid biosimilar/competit
threat larg overblown
diversif
underappreci pipelin model/valu
potenti transform blockbust shot goal increas
pt street-high inclus
underappreci opportun wilson diseas
launch peak sale est po gener
myasthenia gravi gmg launch peak sale po
warm autoimmun hemolyt anemia waiha launch
peak sale po two potenti blockbust opportun
ultomiri two high-risk high-reward potenti blockbust
indic multipl sclerosi launch peak sale
po amyotroph later sclerosi al launch
peak sale po note upsid estim
potenti high-risk high-reward potenti blockbust
al amyloidosi link note approv multi-billion sale
opportun po exhibit price target breakdown across
stori chang tangibl ultomiri switch
rate well ahead expectations/go address previous
stagger us pnh patient initi ultomiri follow
agent fda approv disclosur patient
switch per report link day note importantli
rate soliri switch ultomiri maintain could
achiev goal switch soliri patient ultomiri
littl vs goal within risk concentr
soliri revenu stream next gener competitor
pozelimab link note biosimilar
threat eu ip expir usa ip expir sever
overhang stock larg un-address ahead
switch rate allevi usa biosimilar risk ahead ip expiri
importantli see us experi illustr potenti eu
switch rate soliri revenu cross-hair ahead
ip-expiri continu page
dissemin produc price prior trade day market close estimate unless otherwis note
despit pnh patient competit like soliri
mg approv see declin soliri pnh sale
larg off-set expans ahu mg focu
long-term revenu expens guidanc amid intens
development competit field complement
inhibitor anticip restructur could help remov
near-term overhang stock follow manag
could help protect pnh ahu
market competitor see dose
regimen promis highli conveni though riski
development strategi present pk
dose use remain unclear
whether recycl strategi use extend half
life hold high concentr note
therapeut antibodi commerci
high dose though conced dose would
like seen conveni mani competitor
ip extens like fend soliri biosimilar
see recent composit matter formul
method use patent extend ip us
hold launch biosimilar anticip issuanc
similar patent eu extend protect
eu countri view biosimilar soliri near-term
upcom potenti catalyst eu approv
pnh approv soliri nmosd
initi phase studi nmosd
risk factor neg influenc valuat
rate includ develop setback includ
pnh posit develop
progress competitor complement program
bloomberg capit market estim upside/downside/target
price target base sum-of-the-part
sotp methodolog estim probability-adjust
npv follow soliri sale pnh soliri
sale ahu strensiq sale
share kanuma sale lal-d soliri sale
mg soliri sale nmo
ultomiri sale pnh ultomiri
sale ahu ultomiri
sale neuro sale wilson diseas
compani debt posit price
target support outperform rate
upsid scenario assum
approv wilson diseas po
approv mg waiha po
consensu ultomiri switch biosimilar competit
soliri appear europ increas soliri sale
downsid scenario assum assum
discount soliri npv base earlier-than-
anticip biosimilar entri solri indic
see investor gain comfort ultomiri gain franchis broad though
complet protect eu limit downsid soliri biosimilar link biosimilar
risk scenario analysi note enabl grow revenu potenti biosimilar
conserv model peak sale wilson diseas grow
market though well potenti effect therapi indic
small molecul copper cu bind agent develop treatment copper
accumul wilson diseas sever copper-chel current market
treatment wilson diseas dose safety/toler limit efficaci price
impact uptak competit product cuprimin syprin bausch
report annual sale sale gener competit teva syprin
ad addit im see decis power on-going
trial superior exist therapi ultim grant commerci tailwind
potenti expand market conserv model peak penetr high singl
digit us wilson diseas patient popul anticip see
premium price model usag primarili treatment patient unabl toler
treatment patient unabl toler current chelat low singl
digit penetr treatment elig popul us view copper-
clear efficaci toler superior current soc easl data present note
wilson acquisit note note price pressur space potenti emerg
addit soc gener could limit price power model peak risk-unadjust
sale wilson diseas assign po program result
addit npv-deriv pt look forward evalu addit durabl data
ahead start phase focu trial readout
waiha conserv model peak global sale upsid
price gear toward waiha orphan indic vs gmg recent acquir
broad potenti across varieti igg mediat diseas warm
autoimmun hemolyt anemia waiha one two initi indic target gmg
waiha one four subtyp autoimmun hemolyt anemia
autoantibodi red blood cell reactiv bodi temperatur lead hemolysi
anemia abil reduc half-lif circul igg
autoreact speci demonstr proof concept waiha see high
probabl success trial waiha affect patient us
approxim patient classifi idiopath primari model
treatment primari diseas patient treatment treat corticosteroid /-
transfus assum dose initi weekli dose similar gmg assumpt
current approv therapi moder effect treatment rituximab
splenectomi immunosuppress see captur market
us eu model peak unadjust sale us
eu po importantli could see premium price well beyond
conserv price assum price broad access
gmg model peak global sale aris access/pr
strategi aim broad captur anticip aim extend treatment
option less sever gmg popul vs soliris/ultomiri aim rrmg leverag
sales/market distribut capabl alreadi place soliri refractori mg
popul phase studi expect begin enrol broad popul
mg patient rang mild sever see anti-fcrn target therapi gain top
market share treatment landscap split conserv assumpt given
leadership field among argenx argx efgartigimod momenta
remain earli compar efficaci profil differ agent
abl leverag sales/market distribut capabl alreadi built soliri
sever mg patient popul potenti drive share beyond initi conserv
assumpt conserv model peak unadjust sale us market
launch ex-u market assign po
ultomiri shot goal potenti transform neuromarket see potenti
peak sale al ms though high risk po
plan initi trial examin therapeut potenti ultomiri
amyotroph later sclerosi al primari progress multipl sclerosi ppm
medic literatur provid rational role complement system activ
neurodegen diseas though note compon immun system contribut
diseas pathogenesi well literatur search suggest membran attack
complex complement system compon deposit motor endplat al patient
detect immunostain indic caus role damag nerv tissu
 neuroinflamm addit complement product elev csf
serum al patient neurol neurosurg psychiatri evid anim studi
show transgen mice reduc level surviv longer control mice barnum
scott role termin complement pathway al anoth studi claim
strong neg correl mrna level hind limb muscl strength
neuroinflamm similarli primari progress multipl sclerosi ppm patient
complement activ hallmark cortic grey matter lesion brain patient
neuroinflamm complement marker seen activ inact plaqu
repres demyelin progress ms diseas acta neuropathologica commun
find hint role complement system pathogenesi
arm immun system cell cytokin contribut well therefor
model low po al ppm ad respect pt
addit model risk-unadjust us peak sale ultomiri ppm
risk-unadjust us peak sale ultomiri al
price target base sum-of-the-part sotp methodolog
estim probability-adjust npv follow soliri sale pnh soliri
sale ahu strensiq sale kanuma sale lal-d
soliri sale mg soliri sale nmo ultomiri
sale pnh ultomiri sale ahu ultomiri
sale neuro sale wilson diseas
sale cash compani debt posit
share price target support outperform rate
risk rate price target
factor neg influenc valuat rate includ develop
set-back includ neg readout studi ahu posit develop
progress competitor complement program
alexion pharmaceut global fulli integr biopharmaceut compani
focus treatment rare diseas lead commerci product soliri eculizumab
human monoclon antibodi direct complement factor soliri approv
treatment paroxysm nocturn hemoglobinuria pnh atyp hemolyt urem
syndrom ahu gener myasthenia gravi three ultra-rar diseas caus
uncontrol complement activ alexion aim expand soliri neurolog
transplant disord conduct late-stag develop program neuromyel optica
nmo delay graft function dgf antibody-medi reject amr
alexion also market strensiq asfotas alfa enzym replac therapi ert indic
hypophosphatasia grant us approv octob eu approv
septemb approv japan juli addit
acquisit synageva alexion own kanuma sebelipas alfa ert treatment
lysosom acid lipas defici lal-d receiv eu us market approv
septemb decemb respect approv japan march
compani current develop next gener complement inhibitor
treatment pnh ahu potenti complement associ diseas
compani report capit market estim
compani report capit market estim
chang model revenu expens expens expens incom incom expens incom incom non- non- exhibit wilson diseas us market model
compani report capit market estim
wilson diseas us wilson number wilson diseas patient toler long term toler long term patient toler long term toler long term chelat penetr treatment penetr treatment treat annual list price growth annual net cost quarterli cost wilson total revenu mm wilson diseas wilson diseas wilson diseas wilson diseas ww exhibit waiha us market model
compani report capit market estim
waiha us number aiha waiha waiha patient primari idiopath waiha patient need treat treatment market penetr treat list price growth annual net cost quarterli cost waiha total revenu mm waiha waiha waiha waiha ww exhibit mg us market model
compani report capit market estim
mg us mg adult mg adult mg gener mg gener mg patient anti-achr patient therapi penetr gmg treat gmg gmg treat net annual gmg revenu mm us mg mg mg mg mg ww exhibit ultomiri ppm us eu market model
compani report capit market estim
ppm us scelrosi patient ms patient ppm ultomiri ppm treat ppm patient annual list price growth annual net cost quarterli cost ppm total revenu mm eu scelrosi patient ms patient ppm ultomiri ppm treat ppm patient annual net cost quarterli cost growth ppm total revenu mm ppm ppm ppm ppm ultomiri ppm ww exhibit ultomiri al us market model
compani report capit market estim
al us mutat potenti mutat potenti patient sporad sporad ultomiri penetraiton mutat patient ultomiris- sporad diseas patient benefit sporad diseas patient benefit ultomiri penetr sporad penetr sporad patients- ultomiri treat al patients- ultomiri annual list price growth annual net cost quarterli cost al total revenu mm al al al al ultomiri al ww exhibit
compani report capit market estim
mm fy soliri net ultomiri sale risk adjust net complement net strensiq net kanuma net sale risk adjust net metabol net revenues- sale mg- sale waiha- net product contract research revenues- total gross sg total oper gaap oper incom loss incom gaap net incom gaap incom tax net incom gaap basic ep dilut net incom non-gaap dilut dilut biotechnolog
